Samuel Ellman

Title: Innovations of Samuel Ellman in Biomedical Materials

Introduction

Samuel Ellman is an accomplished inventor based in Troy, NY (US). He has made significant contributions to the field of biomedical materials, particularly through his innovative patent related to drug release systems. His work focuses on the synthesis and processing of poly(pro-drug) materials that offer extended drug release capabilities.

Latest Patents

Ellman's notable patent is titled "Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof." This patent describes a poly(pro-drug) material that incorporates alternating therapeutic compounds and biodegradable hydrocarbyl groups. These components are separated by cleavable linker compounds, allowing for a controlled release of therapeutic agents such as estrogen, curcumin, and fingolimod. The materials are designed to degrade in aqueous media at physiological temperature and pH, releasing therapeutic compounds over extended periods, which can last for years. This innovative approach has potential applications in various biomedical fields, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.

Career Highlights

Samuel Ellman is affiliated with Rensselaer Polytechnic Institute, where he continues to advance his research in biomedical materials. His work has garnered attention for its potential to revolutionize drug delivery systems and improve patient outcomes.

Collaborations

Ellman has collaborated with notable colleagues such as Edmund Francis Palermo and Anthony Richard D'Amato. Their combined expertise contributes to the innovative research being conducted at Rensselaer Polytechnic Institute.

Conclusion

Samuel Ellman's contributions to the field of biomedical materials through his innovative patent demonstrate the potential for significant advancements in drug delivery systems. His work is paving the way for improved therapeutic applications that can enhance patient care and treatment efficacy.